Decentralized Clinical Trials
European Medicines Agency
In-Vitro Diagnostic Regulation
Rare Disease Trials
Research & Development
Latest from Alira Health
We are pleased to announce that we will be sponsoring and attending DPHARM, a unique event focused on the latest innovations that modernize clinical trials.
DTx France 2022
We are pleased to announce that we will be joining as speakers and exhibitors at DTx France 2022. This hybrid event will focus on the latest DTx trends, regulatory framework, market(...)
Advanced Wound Care Summit
Join us at the Advanced Wound Care Summit July 13 – 14 in Boston.
Partners in the Continuum of Drug Development
Listen to the new Empowered Patient Podcast with Karen Jagoda as Gabriele Brambilla, Alira Health CEO, discusses novel approach using technology services to actively engage and partner(...)
The Promise and Reality of NGTs
Listen to the episode “The Promise and Reality of Next Generation Therapies".
Webinar Replay: What You Should Know About MDR Best Practices, Including PMCF
Discover the major changes introduced by the MDR, including the post-market requirements, and especially the Post-Market Clinical Follow-up (PMCF).
La société internationale de conseil en santé Alira Health s’implante à Bordeaux
La société Alira Health poursuit son développement en France avec l’ouverture d’un nouveau bureau à Bordeaux.
Music Beats Cancer Hosts Reception at BIO International Convention in San Diego
Music Beats Cancer hosted a reception fostering a networking community for innovators working on promising solutions for cancer.
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections.
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.